Our team

Our team consists of nearly 200 staffs, including 20 PhDs and master's degree above 30%. The core management team is closely united and has been cooperated for more than a decade. With professional academic background and experiment experience, our team can provide excellent service and quality products for customs. 

Oudong PanPresident, general manager and founder of OBiO Tec

President, general manager and founder of OBiO Technology (Shanghai) Corp., Ltd.
Executive Development Programs, School of Management, Fudan University
2002-2005, general manager & founder of Oubo medical bioengineering technology corp.
2006-2012, general manager, executive director and co-founder of Sbo medical bioengineering technology corp.
2013, established OBiO Technology (Shanghai) Corp., Ltd.
2016, taken OBiO Technology (Shanghai) Corp., Ltd. listed on “National equities exchange and quotations” (NEEQ Market, ID:839702, stock name: Heyuan Shanghai)

Dexian ZhengChief scientist

Zheng Dexian, Ph.D., Professor, Chief Scientist Officer of OBiO Technology (Shanghai) Ltd. Co. since 2016. In Prof. Zheng’s academic career, he has worked in the Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), as a Director of the State key Laboratory of Experimental Hematology, as a Director of the Institute of Basic Medical Sciences and a Dean of College of Basic Medicine, CAMS & PUMC, as an Executive Council Member of International Union for Immunological Societies, as a Member of the Seventh National Committee of the China Association for Science and Technology, as a Vice President of the Chinese Society for Immunology, as a Council Member of the Chinese Society for Biochemistry and Molecular Biology, and etc.

Guodong JiaVice president

2017-Now    OBiO Technology (Shanghai) Corp,. LTD. VP

2009-2016 GE China Lief Sciences Technology Center  RD Director

2004-2009 Tianjin University, Biochemical engineering   Ph.D

VP in OBiO Shanghai, lead the experienced team to provide virus vector CDMO service to gene therapy and cell therapy industry companies. Including lab scale process development, assay development and validation, tech-transfer, scale up, virus drug IND service total solution, GMP manufacturing for Phase I and II, setting up the GMP quality management system, together with the global standard BSL-2 GMP facility construction.Before OBiO, led a technical team in GE global RD center to provide IND service to biopharma companies, built GE China two bridging-Manufacturing pilot platforms for MAB IND.Complete more than 20 process development projects on vaccine, plasma, MABs, R-proteins, Biochemicals, and transfer these project to different companies.Published 8 SCI papers, co editor for 2 CFDA regulatory handbooks, Biopharma chairman in ISPE China committee.Ph.D degree on biochemical engineering, downstream purification background.